Posted inStock
Eli Lilly Stock Slips 1.5% Despite $1,350 Target as Obesity Drugs Drive 45% Revenue Growth
Eli Lilly stock slipped about 1.5% Friday even as Barclays stepped in with a confident call: an Overweight rating and a $1,350 price target. For investors, that mismatch is the…







